Table 1.
A summary of recent publications that used nanocarriers in attempts to improve the efficacy of TMZ
| Main challenges addressed | TMZ-loaded PLGA NPs (poloxomer 80- or polysorbate 80-coated)4,5 | Chitosan/TMZ/biotin-loaded NPs coated with chlorotoxin6 | TMZ-loaded mesoporous silica NPs decorated with a PPNAC targeting miR22110 | TMZ-loaded polymeric NPs incorporated with iron oxide, and delivered by CED11 | TMZ/quercetin-loaded nanoliposomes coated with DSPE-PEG200012 | TMZ-loaded cyclodextrin-based nanosponges14 |
|---|---|---|---|---|---|---|
| Crossing the blood–brain barrier | ✓ | |||||
| Targeted delivery to the tumor site in rodents | ✓ | ✓ | ||||
| Tissue resistance (tested on cell line) | ✓ | ✓ | ✓ | |||
| Cellular uptake (tested on GBM cell line) | ✓ | ✓ | ✓ | ✓ | ||
| In vivo suppression of tumor growth | ✓ |
Abbreviations: CED, convection-enhanced delivery; DSPE-PEG2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; GBM, glioblastoma multiforme; NPs, nanoparticles; PLGA, poly(d,l-lactide-co-glycolide); PPNAC, polyarginine–peptide nucleic acid conjugate; TMZ, temozolomide.